Cargando…

Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “GUNMA0702”

BACKGROUND: Carbon ion Radiotherapy for prostate cancer is widely used, however reports are limited from single institute or short follow up. We performed a prospective observational study (GUNMA0702) to evaluate the feasibility and efficacy of carbon ion radiotherapy for localized and locally advan...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawamura, Hidemasa, Kubo, Nobuteru, Sato, Hiro, Mizukami, Tatsuji, Katoh, Hiroyuki, Ishikawa, Hitoshi, Ohno, Tatsuya, Matsui, Hiroshi, Ito, Kazuto, Suzuki, Kazuhiro, Nakano, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990498/
https://www.ncbi.nlm.nih.gov/pubmed/32000716
http://dx.doi.org/10.1186/s12885-020-6570-8
_version_ 1783492513009500160
author Kawamura, Hidemasa
Kubo, Nobuteru
Sato, Hiro
Mizukami, Tatsuji
Katoh, Hiroyuki
Ishikawa, Hitoshi
Ohno, Tatsuya
Matsui, Hiroshi
Ito, Kazuto
Suzuki, Kazuhiro
Nakano, Takashi
author_facet Kawamura, Hidemasa
Kubo, Nobuteru
Sato, Hiro
Mizukami, Tatsuji
Katoh, Hiroyuki
Ishikawa, Hitoshi
Ohno, Tatsuya
Matsui, Hiroshi
Ito, Kazuto
Suzuki, Kazuhiro
Nakano, Takashi
author_sort Kawamura, Hidemasa
collection PubMed
description BACKGROUND: Carbon ion Radiotherapy for prostate cancer is widely used, however reports are limited from single institute or short follow up. We performed a prospective observational study (GUNMA0702) to evaluate the feasibility and efficacy of carbon ion radiotherapy for localized and locally advanced prostate cancer. METHODS: Between June 2010 and August 2013, 304 patients with localized prostate cancer were treated, with a median follow-up duration of 60 months. All patients received carbon ion radiotherapy with 57.6 Gy (RBE) in 16 fractions over 4 weeks. Hormonal therapy was given according to the risk group. Toxicity was reported according to the Common Toxicity Criteria for Adverse Event, Version 4.0 by the National Cancer Institute. RESULTS: The overall 5-year biochemical relapse-free rate was 92.7%, with rates of 91.7, 93.4, and 92.0% in low-risk, intermediate-risk, and high-risk patients, respectively. The 5-year local control and overall survival rates were 98.4 and 96.6%, respectively. Acute grade 3 or greater toxicity was not observed. Late grade 2 and grade 3 genitourinary and gastrointestinal toxicity rates were 9 and 0.3%, and 0.3, and 0%, respectively. CONCLUSIONS: The present protocol of carbon ion radiotherapy for prostate cancer provided low genitourinary and gastrointestinal toxicity with good biochemical control within 5 years. TRIAL REGISTRATION: University Medical Information Network Clinical Trial Registry number: UMIN000003827.
format Online
Article
Text
id pubmed-6990498
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69904982020-02-03 Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “GUNMA0702” Kawamura, Hidemasa Kubo, Nobuteru Sato, Hiro Mizukami, Tatsuji Katoh, Hiroyuki Ishikawa, Hitoshi Ohno, Tatsuya Matsui, Hiroshi Ito, Kazuto Suzuki, Kazuhiro Nakano, Takashi BMC Cancer Research Article BACKGROUND: Carbon ion Radiotherapy for prostate cancer is widely used, however reports are limited from single institute or short follow up. We performed a prospective observational study (GUNMA0702) to evaluate the feasibility and efficacy of carbon ion radiotherapy for localized and locally advanced prostate cancer. METHODS: Between June 2010 and August 2013, 304 patients with localized prostate cancer were treated, with a median follow-up duration of 60 months. All patients received carbon ion radiotherapy with 57.6 Gy (RBE) in 16 fractions over 4 weeks. Hormonal therapy was given according to the risk group. Toxicity was reported according to the Common Toxicity Criteria for Adverse Event, Version 4.0 by the National Cancer Institute. RESULTS: The overall 5-year biochemical relapse-free rate was 92.7%, with rates of 91.7, 93.4, and 92.0% in low-risk, intermediate-risk, and high-risk patients, respectively. The 5-year local control and overall survival rates were 98.4 and 96.6%, respectively. Acute grade 3 or greater toxicity was not observed. Late grade 2 and grade 3 genitourinary and gastrointestinal toxicity rates were 9 and 0.3%, and 0.3, and 0%, respectively. CONCLUSIONS: The present protocol of carbon ion radiotherapy for prostate cancer provided low genitourinary and gastrointestinal toxicity with good biochemical control within 5 years. TRIAL REGISTRATION: University Medical Information Network Clinical Trial Registry number: UMIN000003827. BioMed Central 2020-01-30 /pmc/articles/PMC6990498/ /pubmed/32000716 http://dx.doi.org/10.1186/s12885-020-6570-8 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kawamura, Hidemasa
Kubo, Nobuteru
Sato, Hiro
Mizukami, Tatsuji
Katoh, Hiroyuki
Ishikawa, Hitoshi
Ohno, Tatsuya
Matsui, Hiroshi
Ito, Kazuto
Suzuki, Kazuhiro
Nakano, Takashi
Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “GUNMA0702”
title Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “GUNMA0702”
title_full Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “GUNMA0702”
title_fullStr Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “GUNMA0702”
title_full_unstemmed Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “GUNMA0702”
title_short Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “GUNMA0702”
title_sort moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “gunma0702”
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990498/
https://www.ncbi.nlm.nih.gov/pubmed/32000716
http://dx.doi.org/10.1186/s12885-020-6570-8
work_keys_str_mv AT kawamurahidemasa moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702
AT kubonobuteru moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702
AT satohiro moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702
AT mizukamitatsuji moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702
AT katohhiroyuki moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702
AT ishikawahitoshi moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702
AT ohnotatsuya moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702
AT matsuihiroshi moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702
AT itokazuto moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702
AT suzukikazuhiro moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702
AT nakanotakashi moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702
AT moderatelyhypofractionatedcarbonionradiotherapyforprostatecanceraprospectiveobservationalstudygunma0702